Company PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Euronext Paris Other stock markets 23:00:00 26/05/2024 BST			5-day change	1st Jan Change
3.03 ^EUR	0.00%		-0.33%	-34.13%

04-15	Phaxiam initiates trial in infective endocarditis	CF
04-15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

Number of employees: 68

Managers	Title	Age	Since
Thibaut du Fayet CEO	Chief Executive Officer	56	22/06/23
Eric Soyer DFI	Director of Finance/CFO	57	22/06/23
Pascal Birman CTO	Chief Tech/Sci/R&D Officer	-	22/06/23
Cindy Fevre CTO	Chief Tech/Sci/R&D Officer	-	22/06/23
Céline Breda CTO	Chief Tech/Sci/R&D Officer	54	22/06/23
Karine Charton PRN	Corporate Officer/Principal	-	22/06/23
Frédérique Vieville LAW	General Counsel	-	22/06/23
Anne-Cécile Fumey HRO	Human Resources Officer	-	22/06/23
Jérôme Bailly PRN	Corporate Officer/Principal	45	22/06/23

Members of the board	Title	Age	Since
Philippe Archinard BRD	Director/Board Member	63	22/06/23
Hilde Windels BRD	Director/Board Member	59	22/06/23
Gil Beyen BRD	Director/Board Member	62	22/06/23
Martine George BRD	Director/Board Member	76	22/06/23
Eric Jean Marie Leire BRD	Director/Board Member	66	22/06/23
Didier Hoch CHM	Chairman	68	22/06/23
Leila Nicolas BRD	Director/Board Member	-	22/06/23
Robert Sebbag BRD	Director/Board Member	73	22/06/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,075,105	5,597,574 ( 92.14 %)	250 ( 0.004115 %)	92.14 %

Name	Equities	%	Valuation
Armistice Capital LLC 2.682 %	162,912	2.682 %	515 613 €
Auriga Partners SA 1.889 %	114,752	1.889 %	363 188 €
RECORDATI 0.7095 %	43,103	0.7095 %	136 420 €
OFI Invest Asset Management SA 0.2780 %	16,886	0.2780 %	53 444 €
BVF Partners LP 0.1602 %	9,734	0.1602 %	30 808 €
OP Asset Management Ltd. 0.1236 %	7,506	0.1236 %	23 756 €
Generali Asset Management SGR SpA 0.1152 %	7,000	0.1152 %	22 155 €
Lyxor International Asset Management SAS 0.0854 %	5,190	0.0854 %	16 426 €
Ecofi Investissements SA 0.0609 %	3,700	0.0609 %	11 710 €
Friedland Gestion SAS 0.0556 %	3,375	0.0556 %	10 682 €

Name	Equities	%	Valuation
Asset Dedication LLC 0.000000 %	0	0.000000 %	- €

Name	Equities	%	Valuation
PHAXIAM THERAPEUTICS S.A. 0.00%	250	0.00%	791 $

PHAXIAM Therapeutics SA

60, avenue Rockefeller Bâtiment Bioserra

69008, Lyon

http://www.phaxiam.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.04 EUR

Average target price

7.05 EUR

Spread / Average Target

+131.91%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PHAXIAM THERAPEUTICS S.A.	-34.13%	20.09M
VERTEX PHARMACEUTICALS INCORPORATED	+9.08%	115B
REGENERON PHARMACEUTICALS, INC.	+9.64%	105B
BIONTECH SE	-12.75%	22.71B
ARGENX SE	+3.20%	21.83B
GENMAB A/S	-10.88%	18.18B
WUXI APPTEC CO., LTD.	-41.92%	16.52B
BEIGENE, LTD.	-16.01%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+1.38%	14.14B
SAREPTA THERAPEUTICS, INC.	+18.00%	10.71B

Bio Therapeutic Drugs